BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xing J, Ying H, Li J, Gao Y, Sun Z, Li J, Bai C, Cheng Y, Wu H. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. Front Oncol 2020;10:132. [PMID: 32181153 DOI: 10.3389/fonc.2020.00132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Rösner E, Kaemmerer D, Sänger J, Lupp A. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Transl Oncol 2022;25:101526. [PMID: 36067541 DOI: 10.1016/j.tranon.2022.101526] [Reference Citation Analysis]
2 Chan D, Rodriguez-freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. European Journal of Cancer 2022;169:74-81. [DOI: 10.1016/j.ejca.2022.03.029] [Reference Citation Analysis]
3 Xu S, Ye C, Chen R, Li Q, Ruan J. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:2911. [PMID: 35740577 DOI: 10.3390/cancers14122911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Garcia-Alvarez A, Cubero JH, Capdevila J. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms? Curr Oncol Rep 2022. [PMID: 35171460 DOI: 10.1007/s11912-022-01235-x] [Reference Citation Analysis]
5 Corbett V, Arnold S, Anthony L, Chauhan A. Management of Large Cell Neuroendocrine Carcinoma. Front Oncol 2021;11:653162. [PMID: 34513663 DOI: 10.3389/fonc.2021.653162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hiltunen N, Väyrynen JP, Böhm J, Helminen O. CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. Diseases 2021;9:42. [PMID: 34208144 DOI: 10.3390/diseases9020042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lee W, Kim MJ, Choi Y, Kim H. PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis. Transl Cancer Res 2021;10:2210-8. [PMID: 35116539 DOI: 10.21037/tcr-20-3482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas 2021;50:500-5. [PMID: 33939660 DOI: 10.1097/MPA.0000000000001794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]